MedPath

Evaluation of the Cardio protective Effect of Melatonin in Acute Aluminum Phosphide Poisoning: A Randomized Clinical Trial

Phase 4
Conditions
aluminum phosphide poisoning
Registration Number
PACTR201911790018554
Lead Sponsor
fatma gaber sobeeh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

All admitted cases above 18 years with acute aluminum phosphide poisoning will be included in this study.

Exclusion Criteria

•Cases ingested or exposed to other substances in addition to the phosphide.
•Cases with delayed presentation.
•Cases with pre-exciting disease (e.g. cardiovascular disease, renal

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
oDetermination of troponin I level and Arterial Blood Gases and oLipid peroxidation (LPO) assessment <br>oTotal antioxidant capacity assessment <br>
Secondary Outcome Measures
NameTimeMethod
•Mortality.<br>•Need for ventilation.<br>•Duration of hospital stay<br>
© Copyright 2025. All Rights Reserved by MedPath